Shares of Iovance Biotherapeutics, Inc. (IOVA) surged on Tuesday after the company reported positive early clinical data for lifileucel in aggressive soft tissue sarcomas.
The stock is currently trading at $3.7014, up $0.8114 or 28.08%, on the Nasdaq. The stock opened at $3.2950 after closing Monday at $2.8900. The stock has traded between $1.6400 and $5.8800 in the past 52-week period. Trading volume more than tripled its daily average.
Iovance reported that in a pilot clinical trial led by Memorial Sloan Kettering Cancer Center, lifileucel achieved a 50% confirmed objective response rate among the first six evaluable patients with advanced undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. The company plans to launch a registrational trial in the second quarter of 2026 and pursue an accelerated regulatory pathway.
Iovance also reported a fourth-quarter net loss of $71.9 million or $0.18 per share, compared to $78.6 million or $0.26 per share last year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.